Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis and lymphoma

Xian Huo Wang, Kai Fu, Qiang Pan-Hammarstrom, Xiubao Ren, Huilai Zhang

Research output: Contribution to journalReview article

Abstract

Immune checkpoints have become one of the most popular areas of cancer therapy. Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis is the most important representative of immune checkpoints until now, and three inhibitors of PD-1/PD-L1 axis have been successfully approved by Food and Drug Administration (FDA). Several clinical trials have confirmed the surprising effects and great clinical application values of PD-1/PD-L1 axis inhibitors. Lymphoma that originates in lymphocytes and differs from other solid tumors has its unique characteristics. It is not only characterized by malignant proliferation, which is similar to that of other solid tumors, but also has some characteristics of lymphocytes including T/B cells. Hence, the regulatory mechanism of PD-1/PD-L1 axis is more complex in lymphoma, making the expression and clinical value of PD-1/PD-L1 in lymphoma more elusive. In this review, we focus on illustrating the specific regulation mechanisms, expression features, clinical treatment and future challenges of PD-1/PD-L1 axis in lymphoma.

Original languageEnglish (US)
Pages (from-to)400-404
Number of pages5
JournalChinese Journal of Microbiology and Immunology (China)
Volume37
Issue number5
DOIs
StatePublished - May 31 2017

Fingerprint

Lymphoma
Ligands
Lymphocytes
Neoplasms
United States Food and Drug Administration
B-Lymphocytes
Clinical Trials
Therapeutics

Keywords

  • Immune checkpoint
  • Lymphoma
  • PD-1/PD-L1 axis

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Virology

Cite this

Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis and lymphoma. / Wang, Xian Huo; Fu, Kai; Pan-Hammarstrom, Qiang; Ren, Xiubao; Zhang, Huilai.

In: Chinese Journal of Microbiology and Immunology (China), Vol. 37, No. 5, 31.05.2017, p. 400-404.

Research output: Contribution to journalReview article

Wang, Xian Huo ; Fu, Kai ; Pan-Hammarstrom, Qiang ; Ren, Xiubao ; Zhang, Huilai. / Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis and lymphoma. In: Chinese Journal of Microbiology and Immunology (China). 2017 ; Vol. 37, No. 5. pp. 400-404.
@article{8e2a5d168b324c85b34cb47f377fba3e,
title = "Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis and lymphoma",
abstract = "Immune checkpoints have become one of the most popular areas of cancer therapy. Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis is the most important representative of immune checkpoints until now, and three inhibitors of PD-1/PD-L1 axis have been successfully approved by Food and Drug Administration (FDA). Several clinical trials have confirmed the surprising effects and great clinical application values of PD-1/PD-L1 axis inhibitors. Lymphoma that originates in lymphocytes and differs from other solid tumors has its unique characteristics. It is not only characterized by malignant proliferation, which is similar to that of other solid tumors, but also has some characteristics of lymphocytes including T/B cells. Hence, the regulatory mechanism of PD-1/PD-L1 axis is more complex in lymphoma, making the expression and clinical value of PD-1/PD-L1 in lymphoma more elusive. In this review, we focus on illustrating the specific regulation mechanisms, expression features, clinical treatment and future challenges of PD-1/PD-L1 axis in lymphoma.",
keywords = "Immune checkpoint, Lymphoma, PD-1/PD-L1 axis",
author = "Wang, {Xian Huo} and Kai Fu and Qiang Pan-Hammarstrom and Xiubao Ren and Huilai Zhang",
year = "2017",
month = "5",
day = "31",
doi = "10.3760/cma.j.issn.0254-5101.2017.05.013",
language = "English (US)",
volume = "37",
pages = "400--404",
journal = "Chinese Journal of Microbiology and Immunology",
issn = "0254-5101",
publisher = "Society of Microbiology and Immunology",
number = "5",

}

TY - JOUR

T1 - Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis and lymphoma

AU - Wang, Xian Huo

AU - Fu, Kai

AU - Pan-Hammarstrom, Qiang

AU - Ren, Xiubao

AU - Zhang, Huilai

PY - 2017/5/31

Y1 - 2017/5/31

N2 - Immune checkpoints have become one of the most popular areas of cancer therapy. Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis is the most important representative of immune checkpoints until now, and three inhibitors of PD-1/PD-L1 axis have been successfully approved by Food and Drug Administration (FDA). Several clinical trials have confirmed the surprising effects and great clinical application values of PD-1/PD-L1 axis inhibitors. Lymphoma that originates in lymphocytes and differs from other solid tumors has its unique characteristics. It is not only characterized by malignant proliferation, which is similar to that of other solid tumors, but also has some characteristics of lymphocytes including T/B cells. Hence, the regulatory mechanism of PD-1/PD-L1 axis is more complex in lymphoma, making the expression and clinical value of PD-1/PD-L1 in lymphoma more elusive. In this review, we focus on illustrating the specific regulation mechanisms, expression features, clinical treatment and future challenges of PD-1/PD-L1 axis in lymphoma.

AB - Immune checkpoints have become one of the most popular areas of cancer therapy. Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis is the most important representative of immune checkpoints until now, and three inhibitors of PD-1/PD-L1 axis have been successfully approved by Food and Drug Administration (FDA). Several clinical trials have confirmed the surprising effects and great clinical application values of PD-1/PD-L1 axis inhibitors. Lymphoma that originates in lymphocytes and differs from other solid tumors has its unique characteristics. It is not only characterized by malignant proliferation, which is similar to that of other solid tumors, but also has some characteristics of lymphocytes including T/B cells. Hence, the regulatory mechanism of PD-1/PD-L1 axis is more complex in lymphoma, making the expression and clinical value of PD-1/PD-L1 in lymphoma more elusive. In this review, we focus on illustrating the specific regulation mechanisms, expression features, clinical treatment and future challenges of PD-1/PD-L1 axis in lymphoma.

KW - Immune checkpoint

KW - Lymphoma

KW - PD-1/PD-L1 axis

UR - http://www.scopus.com/inward/record.url?scp=85031945393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031945393&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.0254-5101.2017.05.013

DO - 10.3760/cma.j.issn.0254-5101.2017.05.013

M3 - Review article

AN - SCOPUS:85031945393

VL - 37

SP - 400

EP - 404

JO - Chinese Journal of Microbiology and Immunology

JF - Chinese Journal of Microbiology and Immunology

SN - 0254-5101

IS - 5

ER -